Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29813717 | 1.00 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL9557085 | 0.87 | TAAR1 (0.63) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL3371633 | 0.82 | TAAR1 (0.74) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL16038467 | 0.81 | TAAR1 (0.67) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL30484686 | 0.80 | TAAR1 (0.46) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL1047725 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL900638 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL17117518 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL8727622 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL6934857 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022015051-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASE | 주식회사 보로노이바이오 | 2022-01-20 | — | — | WO | disclosed |
| WO-2020235902-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | 주식회사 보로노이 (KR) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020149553-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR TREATMENT OF KINASE-RELATED DISEASE | 주식회사 보로노이 | 2020-07-23 | — | — | WO | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1790337-A2 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7087765-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20020004522-A1 | Nervous system disorders | NPS PHARMACEUTICALS, INC. | 2002-01-10 | — | — | US | disclosed |
| EP-1096926-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-2000002551-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0912494-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998056752-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1998-12-17 | — | — | WO | disclosed |
| EP-0831799-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997046511-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1996040097-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004522-A1 | Nervous system disorders | HIF1A, PYGB, LDHB | TAAR1 4211/4885SLC6A3 860/4885DRD2 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.